Q4_Full Presentation_2023

Q4_Full Presentation_202310 Investor presentation Full year 2023 Rare disease sales decreased by 1 manufacturing output DKK billion 20 -15% Reported Rare disease sales Growth at CER 3% 6% 46% -3% -47% 15 10 Rare blood disorders 5 0 Total 1 Rare Haem. Haem. Novo- Rare blood A B Seven ® endocrine disorders 2 disorders 3 1 Total includes “ Other Rare disease ” , which consists of primarily Vagifem ® and Activelle ® ; 2 Comprises NovoSeven ® , NovoEight ® , Esp CER: Constant exchange rates; Haem. A: Haemophilia A; Haem. B: Haemophilia B; NAO: North America operations; IO: Internationa Note: NovoThirteen ® is not shown for Rare blood disorders breakdown, only for the total bar. Unless otherwise specified, sales groPage 139Page 141